SEC Form 4 · accession 0000899243-18-019331
Eidos Therapeutics, Inc. · EIDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Aguiar
Director
Period of report
Jul 1, 2018
Accepted (ET)
Jul 3, 2018 · 7:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001731831
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $20.34 | Jul 1, 2018 | A | 43,056 | A | — | Jun 30, 2028 | Common Stock | 43,056 | 43,056 | D |
Explanation of responses
- F1The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 43,056 stock options (the "Grant") on July 2, 2018. The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following June 29, 2018 subject to the Reporting Person's continued service to the Issuer through each vesting date.